Trial Profile
A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabozantinib (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 08 Feb 2021 Status changed from active, no longer recruiting to completed.
- 15 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 06 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.